1. Luxembourg Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Alvotech

Alvotech

ALVOW
AlvotechUS flagNASDAQ Global Market
0.30
USD
-0.02
- -
2.79BMarket Cap
Alvotech
ALVOW
(NASDAQ Global Market)

Recent

price

0.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-3.56
-0.56
-2.27
-3.49
-1.37
-0.91
-0.54
Book Value per Share
- -
-3.64
-0.7
-2.42
-3.61
-1.47
-1.22
-0.97
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
32
67
37
83
91
490
586
492
Sales/Revenue/Turnover
-192.52
-206.46
-640.31
-417.25
-388.11
14.22
13.34
9.66
Operating Margin (%)
15
16
18
20
24
31
38
41
Depreciation Expense
-210
-170
-102
-514
-552
-232
28
-180
Net Income, GAAP
- -
- -
- -
- -
- -
- -
79.52
373.39
Effective Tax Rate (%)
-657.55
-255.26
-276.04
-618.55
-603.42
-47.35
4.76
-36.51
Profit Margin (%)
- -
35
8
63
-66
262
270
214
Working Capital
- -
669
513
780
1,028
1,148
1,400
1,398
LT Debt
- -
-867
-136
-564
-932
-413
-284
-191
Total Equity
- -
- -
- -
- -
- -
- -
1.65
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
5.76
-4.76
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
49
56
54
LT Borrowings
1,262
1,267
1,264
LT Finance Leases
138
135
134
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
312
312
357
Market Capitalization
203
103
82

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
574
456
545
Cash, Cash Equivalents & STI
172
64
143
Accounts Receivable, Net
70
48
47
Inventories
220
228
227
Total Current Liabilities
304
260
331
Payables & Accruals
215
185
229
ST Debt
49
56
54
Deferred Revenue
30
10
18

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
42.05%
-31.08%
Free Cash Flow
- -
35.39%
-50.2%
Net Income, GAAP
- -
40.61%
-112.04%
Sales/Revenue/Turnover
- -
109.28%
19.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37
199
103
151
490
2025
133
173
114
167
586
2026
106
106
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Leef Brands Inc. (ICNAF)
Fusen Pharmaceutical Company Limited (1652.HK)
Aprogen Biologics Inc. (003060.KS)
YourWay Cannabis Brands Inc. (YOUR.CN)
Kaken Pharmaceutical Co., Ltd. (KKPCF)
Teva Pharmaceutical Industries Limited (TEVA)
Business
Alvotech Alvotech (NASDAQ:ALVOW), founded in 2013 and headquartered in Reykjavik, Iceland, is a biotechnology company that develops and manufactures biosimilar medicines through its subsidiaries to expand global access to affordable biologic treatments. The company employs a vertically integrated approach encompassing cell line development, process development, clinical trials, and commercial-scale manufacturing at facilities in Iceland, Germany, Sweden, Switzerland, and India; it operates across Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa via strategic commercial partnerships. Its pipeline features biosimilar candidates targeting immunology (adalimumab/AVT02 to HUMIRA, ustekinumab/AVT04 to STELARA, golimumab/AVT05 to SIMPONI, vedolizumab/AVT16 to ENTYVIO, certolizumab pegol/AVT10 to CIMZIA, ixekizumab/AVT28 to TALTZ, canakinumab/AVT48 to ILARIS, guselkumab/AVT41 to TREMFYA, ofatumumab/AVT65 to KESIMPTA, dupilumab/AVT19 to DUPIXENT), bone disease (denosumab/AVT03 to PROLIA/XGEVA), ophthalmology (aflibercept/AVT06 to EYLEA), respiratory disease (omalizumab/AVT23 to XOLAIR), and oncology (pembrolizumab/AVT33 to KEYTRUDA), with several candidates approved in regions including the US, Europe/EEA, Japan, Canada, Australia, and others. Recent developments include European Economic Area approval for AVT03 (denosumab biosimilar) and Gobivaz (AVT05 golimumab biosimilar, first-in-market to SIMPONI via Advanz Pharma partnership); expansion of the Advanz Pharma alliance in May 2025 to commercialize three additional candidates (including biosimilars to Ilaris and Kesimpta) for up to $180 million in milestones plus revenue share, targeting over ten reference products in Europe from 2025 through 2030; a June 2025 collaboration with Dr. Reddy's Laboratories to co-develop, manufacture, and commercialize a pembrolizumab (Keytruda) biosimilar globally; and completion of the Xbrane Biopharma R&D acquisition in early June 2025, incorporating approximately 40 employees, operations in Stockholm, Sweden, and a certolizumab pegol (Cimzia) biosimilar candidate for roughly $28.9 million.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Alvotech (ALVO) Q1 2026 Earnings Call Transcript

  • defenseworld.net

    Alvotech (NASDAQ:ALVOW) Sees Significant Decrease in Short Interest

  • defenseworld.net

    Short Interest in Alvotech (NASDAQ:ALVOW) Increases By 32.7%

  • defenseworld.net

    Alvotech (NASDAQ:ALVOW) Stock Price Down 20.3% – Here’s What Happened

  • defenseworld.net

    Alvotech (NASDAQ:ALVOW) Stock Price Up 1.4% – Still a Buy?